12:00 AM
Dec 24, 2012
 |  BioCentury  |  Emerging Company Profile

Aros: Easing IBS pain

Denmark's Aros aims to block GI pain in IBS without side effects or dependency

Aros Pharma ApS has found a new way to treat pain associated with irritable bowel syndrome. The company is developing an ASIC1A antagonist that specifically reduces gastrointestinal pain and could be an effective adjunct therapy to available irritable bowel syndrome treatments.

While there are many pain therapeutics on the market, common side effects make them generally unsuitable to treat gastrointestinal pain.

Opioid analgesics should not be used to treat chronic conditions such as irritable bowel syndrome (IBS) due to the risks of dependency and reduced efficacy over time. Other pain therapeutics such as NSAIDs cause gastrointestinal side effects.

"IBS patients have periods of diarrhea or constipation, or both, so any pain therapeutics that irritate the GI tract are unsuitable because they may actually enhance the underlying mechanisms that are causing the disease," COO Gert Bolwig said.

Aros was formed in 2009 by investors at Novo Seeds and SEED Capital Denmark to identify and develop pharmaceutical candidate projects that were struggling due to the financial crisis. The company...

Read the full 824 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >